These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29700760)

  • 1. Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.
    Hulgan T
    Curr HIV/AIDS Rep; 2018 Jun; 15(3):223-232. PubMed ID: 29700760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 13th annual HIV drug guide.
    Djuricich P; Vázquez E
    Posit Aware; 2009; 20(2):28-55. PubMed ID: 19280745
    [No Abstract]   [Full Text] [Related]  

  • 3. 12th annual HIV drug guide.
    Diaz-Linares M; Vázquez E; Gallant J; Delaney M
    Posit Aware; 2008; 19(1):19-48. PubMed ID: 18546577
    [No Abstract]   [Full Text] [Related]  

  • 4. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
    Dubé MP
    Clin Infect Dis; 2000 Dec; 31(6):1467-75. PubMed ID: 11096014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.
    Lagathu C; Béréziat V; Gorwood J; Fellahi S; Bastard JP; Vigouroux C; Boccara F; Capeau J
    Expert Opin Drug Saf; 2019 Sep; 18(9):829-840. PubMed ID: 31304808
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
    Rolón MJ; Figueroa MI; Sued O; Cahn P
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
    Aguirrebengoa K
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():26-30. PubMed ID: 25542873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.
    Karris MY; Jain S; Day TR; Pérez-Santiago J; Goicoechea M; Dubé MP; Sun X; Spina C; Daar ES; Haubrich RH; Morris S;
    HIV Clin Trials; 2017 Mar; 18(2):67-74. PubMed ID: 28134057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
    Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Ribera E; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Deulofeu R; Perez I; Gatell JM;
    Clin Infect Dis; 2015 Mar; 60(5):811-20. PubMed ID: 25389256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.
    Hileman CO; Funderburg NT
    Curr HIV/AIDS Rep; 2017 Jun; 14(3):93-100. PubMed ID: 28434169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance in treated HIV infection.
    Feeney ER; Mallon PW
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):443-58. PubMed ID: 21663838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.